-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, OI2YTP9QG342EZyGHIRqAs5qnlnl2LMc/cULpfvyqnROE5wPbb13G/6u8J8YaE9s VCxp2YsXCneJmQrbzH/Zjw== 0000950170-97-000126.txt : 19970222 0000950170-97-000126.hdr.sgml : 19970222 ACCESSION NUMBER: 0000950170-97-000126 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 19970212 ITEM INFORMATION: Other events FILED AS OF DATE: 19970212 SROS: AMEX FILER: COMPANY DATA: COMPANY CONFORMED NAME: COLUMBIA LABORATORIES INC CENTRAL INDEX KEY: 0000821995 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 592758596 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-10352 FILM NUMBER: 97525905 BUSINESS ADDRESS: STREET 1: 2665 S BAYSHORE DR PH 11-B CITY: MIAMI STATE: FL ZIP: 33133 BUSINESS PHONE: 305-860-16 MAIL ADDRESS: STREET 1: 2665 SOUTH BAYSHORE DRIVE PH 11-B CITY: MIAMI STATE: FL ZIP: 33133 8-K 1 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of Securities Exchange Act of 1934 FEBRUARY 7, 1997 Date of Report (Date of earliest event reported) COLUMBIA LABORATORIES, INC. (Exact name of registrant as specified in its charter) DELAWARE 1-10352 59-2758596 (State or other jurisdiction of (Commission File Number) (I.R.S. Employer incorporation or organization) Identification No.) 2665 SOUTH BAYSHORE DRIVE MIAMI, FLORIDA 33133 (305) 860-1670 (Address, including zip code and telephone number, including area code, of registrant's principal executive offices) ITEM 5. OTHER EVENTS. On February 7, 1997, the Company received notification from the U.S. Food and Drug Administration approving the Company's Treatment Protocol under its IND for the use of Crinone/registered trademark/, vaginally delivered natural progesterone, in assisted fertility procedures. As a result, through leads generated by the Wyeth-Ayerst institutional sales force, Columbia will shortly begin distributing Crinone to leading infertility clinics throughout the United States. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. COLUMBIA LABORATORIES, INC. DATE: February 12, 1997 By: /s/ MARGARET J. ROELL ------------------------------------------ Margaret J. Roell Vice President-Finance and Administration Chief Financial Officer -----END PRIVACY-ENHANCED MESSAGE-----